BAFF | 合法藥品大搜索

Read More

由 AK Dubey 著作 · 2011 · 被引用 58 次 — Mechanism of action. Belimumab is a fully human IgG1λ recombinant monoclonal antibody directed against BLyS.[18] Specific binding of belimumab with the ... Read More

由 A Srivastava 著作 · 2016 · 被引用 12 次 — Answer: Belimumab is a recombinant, fully human, monoclonal antibody directed against the cytokine BLyS, also known as B-cell activating factor (BAFF).[1] It ... Read More

由 M Frieri 著作 · 2015 · 被引用 31 次 — This article explains the precise mechanism of action of belimumab on the soluble protein BlyS that plays a major role in the pathogenesis of lupus nephritis​. In ... Read More

由 R Lamore III 著作 · 2012 · 被引用 25 次 — In March 2011, the FDA approved belimumab (Benlysta, Human Genome Sciences/GlaxoSmithKline), an innovative therapy for ... Mechanism of Action–. Read More

Mechanism of action — In SLE patients, BAFF is overexpressed, which may cause autoimmune B cell proliferation and survival. Belimumab binds to ... Read More

2018年8月29日 — Belimumab is a recombinant monoclonal antibody which specifically acts against BAFF by binding to soluble BAFF. In lymphoid tissue, ... Read More

2018年8月29日 — Belimumab: therapeutic mechanism and current status of clinical trials. ... Keywords: Belimumab, Systemic lupus erythematosus (SLE), BAFFF, ... Read More

Belimumab binds to soluble BLyS to prevent it from signaling through receptors on normal and autoreactive B cells. A reduction in normal and autoreactive B cell​ ... Read More

由 W Shin 著作 · 2018 · 被引用 16 次 — However, no structure of BAFF in complex with any therapeutic antibody is available, even though the precise mechanism and epitope are crucial ... Read More